BLD1102 is a linker-load conjugate ( Drug-Linker Conjugates for ADC ) consisting of a DNA topoisomerase I inhibitor BCPT02 and a protease-cleavable linker. BLD1102 can be used to synthesize ADCs. BLD1102 can be used in cancer research [1].
In Vitro, BCG033-BLD1102 showed strong antitumor activity in a colorectal cancer PDX model[1].
References:
[1]. Guo C, et al. 1049 TAA antibody library and novel linker/payload BLD1102 for ADC, bispecific ADC and nanobody-drug conjugate development[J]. 2024.
In Vitro, BCG033-BLD1102 showed strong antitumor activity in a colorectal cancer PDX model[1].
References:
[1]. Guo C, et al. 1049 TAA antibody library and novel linker/payload BLD1102 for ADC, bispecific ADC and nanobody-drug conjugate development[J]. 2024.
















